Reimbursement, real-world evidence, and workflow impact reshape device competition

Connected Monitoring Is Becoming a Reimbursement-Driven Platform Market

DexCom’s launch of the G7 15-day CGM in Canada, alongside a raised outlook, underscores how connected monitoring is being pulled by convenience and adherence even as reimbursement remains the near-term constraint. The same demand pattern showed up in market data: U.S. remote patient monitoring reimbursement reached $536 million in 2024, chronic disease management accounted for 44.3% of patient-home-monitoring value, and diabetes remains the largest demand engine, with 589 million adults affected in 2024 and 853 million projected by 2050.

AI-enabled monitoring is also broadening the category, with Rokit Healthcare launching an AI skin device in China and Seers partnering with ZeroWeb. At the same time, cataract surgery continues shifting outpatient, with cataract extraction expected to represent about 18% of fee-for-service Medicare ASC volume in 2026.

The strategic takeaway is clear: value is moving from standalone devices to integrated sensing, analytics, and workflow platforms. That makes CMS’s CY 2027 proposal pivotal, because limiting RPM/RTM reimbursement to monitoring staff who are direct employees of the billing practice would weaken outsourced digital-health models, especially for rural Medicare patients and smaller practices. Winners will be reimbursement-resilient platforms with recurring software and service revenue, not hardware alone.

Evidence Infrastructure Becomes the AI Device Moat

FDA this week reinforced its shift toward real-world evidence in device regulation, extending a pattern that already underpinned 73 medical-device marketing authorizations in FY2020-FY2025 and new guidance effective February 17, 2026. Recent clearances show how broad that evidence base has become: Luminopia’s January 10, 2025 510(k) used registry data to expand its indication to children 8 to under 13, while FDA also cited medical records and commercial insurance claims; Bunkerhill AI’s September 19, 2025 software clearance relied on medical-record data from geographically distributed U.S. sites; and FDA’s earlier da Vinci Xi/X summaries drew on medical records, chargemaster data, and Premier Health Database information for a bariatric labeling expansion.

In Europe, Tempus won EU IVDR Class C approval for an AI-enabled diagnostic, while AdvaMed pressed FDA for risk-based oversight of generative AI and FDA said AI and robotics guidance is targeted for 2027. The strategic shift is clear: AI-enabled device competition is moving from best algorithm to best evidence package. Regulators are increasingly rewarding products that can prove routine-care performance across registries, EHRs, claims, and post-market data, making evidence generation a core product capability tied to label expansion, regulatory credibility, and adoption. For operators and vendors, launch planning now needs embedded registries and linked longitudinal datasets; for investors, durable data access and scalable evidence infrastructure are becoming the moat.

Surgical Robotics Becomes a Throughput and Portfolio Game

On October 21, 2026, Distalmotion raised up to $70 million in senior secured term debt from Perceptive Advisors to accelerate U.S. commercialization of DEXTER, signaling that surgical robotics is now being financed around outpatient throughput, not just capital replacement. The company said the money will fund U.S. sales expansion, instrument growth, product iterations, and adoption across four cleared outpatient procedures: cholecystectomy, inguinal hernia repair, ventral hernia repair, and hysterectomy.

The same week, Zimmer Biomet widened its robotics footprint with ROSA Knee with OptimiZe in India, extended TMINI through its THINK Surgical partnership, and pointed to early ROSA Shoulder adoption. On the demand side, Sanford Bismarck added a da Vinci 5 to its three-system fleet to cut wait times, while Apollo Hospitals launched da Vinci 5 in India and completed the country’s first procedure on the platform.

The strategic shift is clear: robotics is moving from a premium device purchase to a platform-and-throughput model. Winners will be the vendors that can prove procedure-specific efficiency, fit ambulatory settings, and leverage broader product portfolios to win share across orthopedics and soft-tissue surgery.

Care Delivery and Local Manufacturing Are Repricing Device Demand

Ontario is set to remove the adult prescription requirement for mild-to-moderate hearing loss in its 2026 Fall Economic Statement, creating an OTC path for Health Canada-authorized self-fitting hearing products. That shift should favor Apple’s hearing-enabled AirPods first, then other authorized earbuds and retail channels such as electronics stores and pharmacies, while Ontario’s Assistive Devices Program is expected to keep subsidizing prescribed aids and leave OTC products outside reimbursement.

The same decentralization is showing up in procedures and home care. Axora’s HERizon RD5 is a single-use, battery-powered 5Fr handheld device designed to let office hysteroscopy and polypectomy happen in one visit without a console or wall power, a workflow gain that is clearer than any reimbursement or comparative-safety advantage. In parallel, Parkinson’s monitoring, home ICU models, and AI-enabled remote care continued to expand, while Happy Health raised $75 million in August 2026 to scale its wearable platform beyond sleep apnea. OMRON also started local blood pressure monitor production in India as China pushed domestic biologic manufacturing, underscoring how localization is reshaping both access and competitive positioning.

Clinical AI Is Shifting From Model Performance to Regulated Workflow Impact

AI clinical software advanced on two fronts this week: stronger validation and clearer evidence that it can change downstream care. In ER+/HER2− early breast cancer, an AI pathology model that infers Oncotype DX recurrence risk from H&E slides plus clinical data validated in the TAILORx cohort of 2,407 patients, with an AUC of 0.898 for high genomic risk and a 98.2% negative predictive value for excluding high risk. In breast imaging, Koios DS, an FDA-cleared ultrasound decision-support tool, was prospectively evaluated at two academic centers and classified 126 of 208 benign BI-RADS 4 lesions, or 60.6%, as BI-RADS 2 or 3, suggesting meaningful biopsy avoidance if radiologists accept the downgrade.

The strategic shift is from static diagnostic features to governed clinical software platforms. Commercial value now depends less on headline accuracy than on whether AI can alter utilization while matching the evidence bar of established assays. With the FDA’s final PCCP guidance in August 2025 and the EU AI Act tightening requirements for predefined modification protocols, impact assessment, and version traceability, retraining and updates are becoming part of the regulated product. Buyers will favor vendors that pair clinical validation with disciplined MLOps and regulator-ready update pathways.